HSP90 inhibitors have been shown to ameliorate inflammation in ulcerative colitis by enhancing the secretion of the anti-inflammatory cytokine IL-10, increasing the number of regulatory T cells (Tregs), and attenuating inflammatory activation (Collins et al., 2013). The gene discussed is HSP90AA1; the disease is ulcerative colitis.